Journal article

Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study

Lieske H Schrijver, Hakan Olsson, Kelly-Anne Phillips, Mary Beth Terry, David E Goldgar, Karin Kast, Christoph Engel, Thea M Mooij, Julian Adlard, Daniel Barrowdale, Rosemarie Davidson, Ros Eeles, Steve Ellis, D Gareth Evans, Debra Frost, Louise Izatt, Mary E Porteous, Lucy E Side, Lisa Walker, Pascaline Berthet Show all

JNCI Cancer Spectrum | OXFORD UNIV PRESS | Published : 2018

Abstract

Background: For BRCA1 and BRCA2 mutation carriers, the association between oral contraceptive preparation (OCP) use and breast cancer (BC) risk is still unclear. Methods: Breast camcer risk associations were estimated from OCP data on 6030 BRCA1 and 3809 BRCA2 mutation carriers using age-dependent Cox regression, stratified by study and birth cohort. Prospective, left-truncated retrospective and full-cohort retrospective analyses were performed. Results: For BRCA1 mutation carriers, OCP use was not associated with BC risk in prospective analyses (hazard ratio [HR] = 1.08, 95% confidence interval [CI] = 0.75 to 1.56), but in the left-truncated and full-cohort retrospective analyses, risks wer..

View full abstract

Grants

Awarded by Cancer Research-UK


Awarded by US National Cancer Institute


Awarded by Spanish Ministry of Economy and Competitiveness (MINECO)


Awarded by Canadian Institutes of Health Research (CIHR)


Awarded by Ministry of Economic Development, Innovation and Export Trade


Awarded by Government of Canada through Canadian Institutes of Health Research


Awarded by Cancer Research UK


Awarded by German Cancer Aid


Awarded by Institute National du Cancer (INCa) as part of the European program ERA-NET on Translational Cancer Research (TRANSCAN-JTC2012)


Awarded by ISCIII (Spain) - European Regional Development FEDER funds


Awarded by Dutch Cancer Society


Awarded by Netherlands Organisation of Scientific Research grant


Awarded by Pink Ribbon grants


Awarded by Biobanking and BioMolecular resources Research Infrastructure (BBMRI) grant Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO)


Awarded by Transcan grant


Awarded by National Centre for Research and Development (NCBR)


Awarded by Cancer Australia


Awarded by Australian National Breast Cancer Foundation


Awarded by National Health and Medical Research Council


Awarded by US National Institutes of Health


Awarded by MH CZ - DRO (MMCI)


Awarded by Hungarian Research grants


Awarded by Norwegian EEA Financial Mechanism


Awarded by European Research Council Advanced Grant



Funding Acknowledgements

This work was supported by Cancer Research-UK grants C12292/A20861 and C12292/A11174.Study-specific funding: The Breast Cancer Family Registry (BCFR) was supported by grant UM1 CA164920 from the US National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR.This work was partially supported by the Spanish Ministry of Economy and Competitiveness (MINECO) SAF2014-57680-R and the Spanish Research Network on Rare diseases (CIBERER). This work was partially supported by FISPI05/2275 and the Mutua Madrilena Foundation (FMMA).Part of this work was supported by the Canadian Institutes of Health Research (CIHR) for the "CIHR Team in Familial Risks of Breast Cancer" program (grant No. CRN-87521) and the Ministry of Economic Development, Innovation and Export Trade (grant No. PSR-SIIRI-701). The PErsonalised Risk Stratification for Prevention and Early deteCTIon of breast cancer (PERSPECTIVE) project was supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research (GPH-129344), the Ministe` re de l'Economie, de la Science et de l' Innovation du Quebec through Genome Quebec, and The Quebec Breast Cancer Foundation. The German Cancer Research Center (DKFZ) study was supported by the German Cancer Research Center (DKFZ).Epidemiological Study of Familial Breast Cancer (EMBRACE) is supported by Cancer Research UK Grants C1287/A10118 and C1287/A11990. D. Gareth Evans is supported by a National Institute for Health Research (NIHR) grant to the Biomedical Research Centre, Manchester. The Investigators at The Institute of Cancer Research and The Royal Marsden National Health Service (NHS) Foundation Trust are supported by an NIHR grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. Ros Eeles and Elizabeth Bancroft are supported by Cancer Research UK Grant C5047/A8385. Ros Eeles is also supported by NIHR support to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. Antonis C. Antoniou is funded by Cancer Research-UK grants C12292/A20861 and C12292/A11174.The German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC) is supported by the German Cancer Aid (grant No. 110837, Rita K. Schmutzler). This work was supported by LIFE-Leipzig Research Center for Civilization Diseases, Universitat Leipzig. LIFE is funded by the European Union, the European Regional Development Fund (ERDF), and the Free State of Saxony within the framework of the excellence initiative.The national French cohort, Gene Etude Prospective Sein Ovaire (GENEPSO), had been supported by a grant from the Fondation de France and grants from the Ligue Nationale Contre le Cancer and is supported by a grant from Institute National du Cancer (INCa) as part of the European program ERA-NET on Translational Cancer Research (TRANSCAN-JTC2012, No. 2014-008).Hospital Clinico San Carlos (HCSC) was supported by grants RD12/0036/0006 and 15/00059 from ISCIII (Spain), which is partially supported by European Regional Development FEDER funds.The Hereditary Breast and Ovarian cancer study Netherlands (HEBON) study is supported by the Dutch Cancer Society grants NKI1998-1854, NKI2004-3088, and NKI2007-3756, the Netherlands Organisation of Scientific Research grant NWO 91109024, the Pink Ribbon grants 110005 and 2014-187.WO76, the Biobanking and BioMolecular resources Research Infrastructure (BBMRI) grant Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO) 184.021.007/CP46, and the Transcan grant JTC 2012 Cancer 12-054.The International Hereditary Cancer Centre (IHCC) was supported by grant PBZ_KBN_122/P05/2004 and The National Centre for Research and Development (NCBR) within the framework of the international ERA-NET TRANSAN JTC 2012, application No. Cancer 12-054 (Contract No. ERA-NET-TRANSCAN/07/2014).This work was also partially supported by grants to Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) and the kConFab FollowUp Study from Cancer Australia (809195), the Australian National Breast Cancer Foundation (IF 17), the National Health and Medical Research Council (454508, 288704, 145684), the US National Institutes of Health (1RO1CA159868), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, and the Cancer Foundation of Western Australia. KAP is an Australian National Breast Cancer Foundation fellow.Modifier Study of Quantitative Effects on Disease (MODSQUAD)-Czech Republic, Brno, was supported by MH CZ - DRO (MMCI, 00209805) and by MEYS - NPS I - LO1413 to LF, MN.The Hungarian Breast and Ovarian Cancer Study was supported by Hungarian Research grants KTIA-OTKA CK-80745 and NKFI OTKA K-112228 and the Norwegian EEA Financial Mechanism HU0115/NA/2008-3/_OP-9.Lund-BRCA collaborators are supported by the Swedish Cancer Society, Lund Hospital Funds, and European Research Council Advanced Grant ERC-2011-294576. Stockholm-BRCA collaborators are supported by the Swedish Cancer Society.